董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | Chief Executive Officer,Director | 59 | 154.70万美元 | 未持股 | 2023-02-10 |
| Derek DiRocco | 男 | Director | 42 | 未披露 | 未持股 | 2023-02-10 |
| Jon Congleton | 男 | Chief Executive Officer,Director | 59 | 未披露 | 未持股 | 2023-02-10 |
| Brian Taylor Slingsby | 男 | Executive Chairman,Founder | 46 | 未披露 | 未持股 | 2023-02-10 |
| Alexander Asam | 男 | Director | 57 | 未披露 | 未持股 | 2023-02-10 |
| Olivier Litzka | 男 | Director | 54 | 未披露 | 未持股 | 2023-02-10 |
| Takeshi Takahashi | 男 | Director | 47 | 未披露 | 未持股 | 2023-02-10 |
| Srinivas Akkaraju | 男 | Director | 54 | 未披露 | 未持股 | 2023-02-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | Chief Executive Officer,Director | 59 | 154.70万美元 | 未持股 | 2023-02-10 |
| David Rodman | 男 | Chief Medical Officer | 67 | 91.57万美元 | 未持股 | 2023-02-10 |
| Adam Levy | 男 | Chief Financial Officer, Chief Business Officer & Secretary | 44 | 82.57万美元 | 未持股 | 2023-02-10 |
| Jon Congleton | 男 | Chief Executive Officer,Director | 59 | 未披露 | 未持股 | 2023-02-10 |
| Brian Taylor Slingsby | 男 | Executive Chairman,Founder | 46 | 未披露 | 未持股 | 2023-02-10 |
董事简历
中英对照 | 中文 | 英文- Jon Congleton
-
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. - Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- Derek DiRocco
-
Derek DiRocco自2021年11月起在Acrivon Therapeutics，Inc.董事会任职。DiRocco博士自2020年12月起担任投资经理RA Capital Management，LLC的合伙人，此前曾于2017年12月至2020年12月担任首席分析师，于2015年6月至2017年12月担任分析师，并于2013年7月至2015年6月担任助理。DiRocco博士自2018年4月起担任89bio董事会成员，自2020年3月起担任iTeos Therapeutics董事会成员，自2020年8月起担任Connect Biopharma Holdings Limited董事会成员，自2020年12月起担任Werewolf Therapeutics公司董事会成员。他此前于2019年9月至2022年5月在Achilles Therapeutics plc董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位，并在布莱根妇女医院/哈佛医学院进行博士后研究。
Derek DiRocco,has been a partner at RA Capital Management, LLC, an investment manager, since December 2020 and previously served as principal from December 2017 to December 2020, an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the board of directors of 89bio, Inc. since April 2018, iTeos Therapeutics, Inc. since March 2020, Frontier Medicines since July 2021, Connect Biopharma Holdings Limited since August 2020, and Werewolf Therapeutics, Inc. since December 2020. He previously served on the board of directors of Achilles Therapeutics plc from September 2019 to May 2022. Dr. DiRocco holds a B.A. in biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington, and conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School. - Derek DiRocco自2021年11月起在Acrivon Therapeutics，Inc.董事会任职。DiRocco博士自2020年12月起担任投资经理RA Capital Management，LLC的合伙人，此前曾于2017年12月至2020年12月担任首席分析师，于2015年6月至2017年12月担任分析师，并于2013年7月至2015年6月担任助理。DiRocco博士自2018年4月起担任89bio董事会成员，自2020年3月起担任iTeos Therapeutics董事会成员，自2020年8月起担任Connect Biopharma Holdings Limited董事会成员，自2020年12月起担任Werewolf Therapeutics公司董事会成员。他此前于2019年9月至2022年5月在Achilles Therapeutics plc董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位，并在布莱根妇女医院/哈佛医学院进行博士后研究。
- Derek DiRocco,has been a partner at RA Capital Management, LLC, an investment manager, since December 2020 and previously served as principal from December 2017 to December 2020, an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the board of directors of 89bio, Inc. since April 2018, iTeos Therapeutics, Inc. since March 2020, Frontier Medicines since July 2021, Connect Biopharma Holdings Limited since August 2020, and Werewolf Therapeutics, Inc. since December 2020. He previously served on the board of directors of Achilles Therapeutics plc from September 2019 to May 2022. Dr. DiRocco holds a B.A. in biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington, and conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School.
- Jon Congleton
-
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在梯瓦制药工业有限公司（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任梯瓦全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入梯瓦公司之前，康格尔顿曾在赛诺菲的前身公司担任过十年的各种商业职务。康格尔顿先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. - Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在梯瓦制药工业有限公司（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任梯瓦全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入梯瓦公司之前，康格尔顿曾在赛诺菲的前身公司担任过十年的各种商业职务。康格尔顿先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- Brian Taylor Slingsby
-
Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University. - Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
- Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University.
- Alexander Asam
-
Alexander Asam自2021年2月起担任Mineralys Therapeutics，Inc.董事会成员。自2007年以来，Asam博士一直担任HBM合伙公司的投资顾问，并在生命科学和私募股权领域带来20多年的经验。2001年至2007年，他曾担任德意志风险投资公司/德意志银行的董事总经理和合伙人，曾在Hoechst AG、Aventis S.A.（现名：赛诺菲）和LION Bioscience AG等公司担任多个职位，并担任IPO核心团队（德国和美国双重上市公司）的成员。他是1000Farmacia Research的董事会成员，也是Swixx Biopharma和Aculys的董事会观察员。2019年10月至2020年10月，阿萨姆博士在上市公司Arcutis Biotherapeutics的董事会任职。Asam博士拥有伯明翰阿斯顿商学院的工商管理硕士学位和海德堡大学的化学硕士和博士学位。
Alexander Asam,has served on Mineralys Therapeutics, Inc. board of directors since February 2021. Since 2007, Dr. Asam has been an Investment Advisor of HBM Partners and brings more than 20 years of experience in the life sciences and private equity businesses. He was a former managing director and partner of Deutsche Venture Capital / Deutsche Bank from 2001 to 2007 and held various positions at Hoechst AG, Aventis S.A. (now: Sanofi) and LION Bioscience AG, among others, as well as a member of the IPO Core Team (dual listing Germany and USA). He is a board member of 1000Farmacia Research, as well as a board observer at Swixx Biopharma and Aculys. Dr. Asam served on the board of directors of publicly-traded Arcutis Biotherapeutics from October 2019 until October 2020. Dr. Asam holds an M.B.A. degree from Aston Business School, Birmingham and a M.Sc. and Ph.D. in chemistry from University of Heidelberg. - Alexander Asam自2021年2月起担任Mineralys Therapeutics，Inc.董事会成员。自2007年以来，Asam博士一直担任HBM合伙公司的投资顾问，并在生命科学和私募股权领域带来20多年的经验。2001年至2007年，他曾担任德意志风险投资公司/德意志银行的董事总经理和合伙人，曾在Hoechst AG、Aventis S.A.（现名：赛诺菲）和LION Bioscience AG等公司担任多个职位，并担任IPO核心团队（德国和美国双重上市公司）的成员。他是1000Farmacia Research的董事会成员，也是Swixx Biopharma和Aculys的董事会观察员。2019年10月至2020年10月，阿萨姆博士在上市公司Arcutis Biotherapeutics的董事会任职。Asam博士拥有伯明翰阿斯顿商学院的工商管理硕士学位和海德堡大学的化学硕士和博士学位。
- Alexander Asam,has served on Mineralys Therapeutics, Inc. board of directors since February 2021. Since 2007, Dr. Asam has been an Investment Advisor of HBM Partners and brings more than 20 years of experience in the life sciences and private equity businesses. He was a former managing director and partner of Deutsche Venture Capital / Deutsche Bank from 2001 to 2007 and held various positions at Hoechst AG, Aventis S.A. (now: Sanofi) and LION Bioscience AG, among others, as well as a member of the IPO Core Team (dual listing Germany and USA). He is a board member of 1000Farmacia Research, as well as a board observer at Swixx Biopharma and Aculys. Dr. Asam served on the board of directors of publicly-traded Arcutis Biotherapeutics from October 2019 until October 2020. Dr. Asam holds an M.B.A. degree from Aston Business School, Birmingham and a M.Sc. and Ph.D. in chemistry from University of Heidelberg.
- Olivier Litzka
-
Olivier Litzka自2022年6月起担任Mineralys Therapeutics，Inc.董事会成员。Litzka博士自2006年起担任风险投资公司Andera Partners的合伙人，并于1998年在美世管理咨询公司开始了他的商业生涯。2000年，他加入3i集团，专注于生物制药和医疗技术投资。Litzka博士目前在MMI Microsystems、T-Knife、Allecra Therapeutics、HighLife Medical、MedLumics、Tricares和JenaValve等公司任职。他还是Corvidia、Sapiens、Endosense、Novexel、Supersonic Imagine和Arvelle Therapeutics的董事会成员，直到他们各自被收购。Litzka博士拥有慕尼黑基因与微生物学研究所的分子微生物学博士学位。
Olivier Litzka,has served on Mineralys Therapeutics, Inc. board of directors since June 2022. Dr. Litzka has served as a partner at Andera Partners, a venture capital firm, since 2006 and started his business career in 1998 with Mercer Management Consulting. In 2000, he joined 3i Group plc with a focus on biopharma and medtech investments. Dr. Litzka currently serves on the boards of MMI Microsystems, T-Knife, Allecra Therapeutics, HighLife Medical, MedLumics, Tricares and JenaValve. He was also a board member of Corvidia, Sapiens, Endosense, Novexel, Supersonic Imagine and Arvelle Therapeutics, up until their respective acquisitions. Dr. Litzka has a Ph.D. in molecular microbiology from the Institut für Genetik und Mikrobiologie in Munich. - Olivier Litzka自2022年6月起担任Mineralys Therapeutics，Inc.董事会成员。Litzka博士自2006年起担任风险投资公司Andera Partners的合伙人，并于1998年在美世管理咨询公司开始了他的商业生涯。2000年，他加入3i集团，专注于生物制药和医疗技术投资。Litzka博士目前在MMI Microsystems、T-Knife、Allecra Therapeutics、HighLife Medical、MedLumics、Tricares和JenaValve等公司任职。他还是Corvidia、Sapiens、Endosense、Novexel、Supersonic Imagine和Arvelle Therapeutics的董事会成员，直到他们各自被收购。Litzka博士拥有慕尼黑基因与微生物学研究所的分子微生物学博士学位。
- Olivier Litzka,has served on Mineralys Therapeutics, Inc. board of directors since June 2022. Dr. Litzka has served as a partner at Andera Partners, a venture capital firm, since 2006 and started his business career in 1998 with Mercer Management Consulting. In 2000, he joined 3i Group plc with a focus on biopharma and medtech investments. Dr. Litzka currently serves on the boards of MMI Microsystems, T-Knife, Allecra Therapeutics, HighLife Medical, MedLumics, Tricares and JenaValve. He was also a board member of Corvidia, Sapiens, Endosense, Novexel, Supersonic Imagine and Arvelle Therapeutics, up until their respective acquisitions. Dr. Litzka has a Ph.D. in molecular microbiology from the Institut für Genetik und Mikrobiologie in Munich.
- Takeshi Takahashi
-
Takeshi Takahashi自2020年5月起担任Mineralys Therapeutics，Inc.董事会成员。高桥先生是Catalys Pacific的执行合伙人，自2019年起担任该职位。在加入Catalys Pacific之前，他在摩根士丹利担任了12年的投资银行家。在为摩根士丹利工作之前，他曾在美林证券的资产管理部门工作。高桥先生毕业于早稻田大学，获得政治学和经济学学位，并拥有西北大学凯洛格管理学院的工商管理硕士学位。
Takeshi Takahashi,has served on Mineralys Therapeutics, Inc. board of directors since May 2020. Mr. Takahashi is the Managing Partner at Catalys Pacific, a position he has held since 2019. Prior to Catalys Pacific, he was an investment banker with Morgan Stanley for 12 years. Prior to working for Morgan Stanley, he worked at Merrill Lynch's asset management division. Mr. Takahashi graduated from Waseda University with a degree in Political Science and Economics and holds an M.B.A. from Kellogg School of Management at Northwestern University. - Takeshi Takahashi自2020年5月起担任Mineralys Therapeutics，Inc.董事会成员。高桥先生是Catalys Pacific的执行合伙人，自2019年起担任该职位。在加入Catalys Pacific之前，他在摩根士丹利担任了12年的投资银行家。在为摩根士丹利工作之前，他曾在美林证券的资产管理部门工作。高桥先生毕业于早稻田大学，获得政治学和经济学学位，并拥有西北大学凯洛格管理学院的工商管理硕士学位。
- Takeshi Takahashi,has served on Mineralys Therapeutics, Inc. board of directors since May 2020. Mr. Takahashi is the Managing Partner at Catalys Pacific, a position he has held since 2019. Prior to Catalys Pacific, he was an investment banker with Morgan Stanley for 12 years. Prior to working for Morgan Stanley, he worked at Merrill Lynch's asset management division. Mr. Takahashi graduated from Waseda University with a degree in Political Science and Economics and holds an M.B.A. from Kellogg School of Management at Northwestern University.
- Srinivas Akkaraju
-
Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University. - Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
- Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.
高管简历
中英对照 | 中文 | 英文- Jon Congleton
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.- Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- David Rodman
David Rodman是我们研发的执行Vice President。David于2017年加入ProQR，此前曾在Novartis Institute for Biomedical Research NIBR，Vertex Pharmaceuticals，Miragen Therapeutics和Nivalis Therapeutics担任领导职务。在2005年转到工业之前，David拥有杰出的学术生涯，领导科罗拉多大学遗传肺部疾病中心，并指导科罗拉多州丹佛市国家犹太医学和研究中心的囊性纤维化护理，教学和研究工作。在工业领域的12年中，David一直负责推动创新，将尖端科学转化为罕见疾病的变革性新疗法，包括CF，肺纤维化，肺动脉高压以及严重的免疫性和炎症性疾病。在Vertex Pharmaceuticals，他指导早期和晚期CF临床开发计划，包括Kalydeco®；，Orkambi®；和VX-661。David于1976年获得Haverford College经济学学士学位，1980年获得University of Pennsylvania医学博士学位，并在University of Colorado完成内科、肺部和重症监护医学培训。他曾担任the National Institutes of Health的顾问，入选美国临床研究学会（the American Society for Clinical Research），是美国心脏协会（the American Heart Association）的院士。
David Rodman is our Executive Vice President of Research & Development. David joined ProQR in 2017 having previously served in leadership roles with Novartis Institutes for Biomedical Research NIBR, Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics. Prior to moving to industry in 2005 David had a distinguished academic career, leading the Center for Genetic Lung Diseases at the University of Colorado and directing the Cystic Fibrosis Care, Teaching and Research efforts at the National Jewish Medical and Research Center in Denver, Colorado. During 12 years in industry, David has had global responsibility for driving innovation in the translation of cutting-edge science into transformational new therapies for rare diseases including CF, pulmonary fibrosis, pulmonary artery hypertension and severe immunologic and inflammatory diseases. At Vertex Pharmaceuticals he directed early- and late-stage CF clinical development programs including Kalydeco®, Orkambi® and VX-661. David received a BA in Economics from Haverford College in 1976 an MD from the University of Pennsylvania in 1980 and completed training in Internal Medicine, Pulmonary and Critical Care Medicine at the University of Colorado. He has served as an advisor to the National Institutes of Health, was elected to the American Society for Clinical Investigation and is a Fellow of the American Heart Association.- David Rodman是我们研发的执行Vice President。David于2017年加入ProQR，此前曾在Novartis Institute for Biomedical Research NIBR，Vertex Pharmaceuticals，Miragen Therapeutics和Nivalis Therapeutics担任领导职务。在2005年转到工业之前，David拥有杰出的学术生涯，领导科罗拉多大学遗传肺部疾病中心，并指导科罗拉多州丹佛市国家犹太医学和研究中心的囊性纤维化护理，教学和研究工作。在工业领域的12年中，David一直负责推动创新，将尖端科学转化为罕见疾病的变革性新疗法，包括CF，肺纤维化，肺动脉高压以及严重的免疫性和炎症性疾病。在Vertex Pharmaceuticals，他指导早期和晚期CF临床开发计划，包括Kalydeco®；，Orkambi®；和VX-661。David于1976年获得Haverford College经济学学士学位，1980年获得University of Pennsylvania医学博士学位，并在University of Colorado完成内科、肺部和重症监护医学培训。他曾担任the National Institutes of Health的顾问，入选美国临床研究学会（the American Society for Clinical Research），是美国心脏协会（the American Heart Association）的院士。
- David Rodman is our Executive Vice President of Research & Development. David joined ProQR in 2017 having previously served in leadership roles with Novartis Institutes for Biomedical Research NIBR, Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics. Prior to moving to industry in 2005 David had a distinguished academic career, leading the Center for Genetic Lung Diseases at the University of Colorado and directing the Cystic Fibrosis Care, Teaching and Research efforts at the National Jewish Medical and Research Center in Denver, Colorado. During 12 years in industry, David has had global responsibility for driving innovation in the translation of cutting-edge science into transformational new therapies for rare diseases including CF, pulmonary fibrosis, pulmonary artery hypertension and severe immunologic and inflammatory diseases. At Vertex Pharmaceuticals he directed early- and late-stage CF clinical development programs including Kalydeco®, Orkambi® and VX-661. David received a BA in Economics from Haverford College in 1976 an MD from the University of Pennsylvania in 1980 and completed training in Internal Medicine, Pulmonary and Critical Care Medicine at the University of Colorado. He has served as an advisor to the National Institutes of Health, was elected to the American Society for Clinical Investigation and is a Fellow of the American Heart Association.
- Adam Levy
Adam Levy自2019年起担任Private Brickell&；8217；S首席商务官。在加入Private Brickell之前，Levy先生于2016年至2019年担任MiragenTherapeutics，Inc.首席商务官纳斯达克股票代码:MGEN，一家临床阶段的生物制药公司，致力于发现和开发专有的RNA靶向疗法，特别关注microRNA及其在医疗需求高度未满足的疾病中的作用。Levy从2000年到2016年在Merrill Lynch，Pierce，Fenner&Smith Incorporated，Jefferies Group和Wedbush Securities Inc.担任多个投资银行职位。Levy先生在康奈尔大学（Cornell University）获得应用经济学学士学位。
Adam Levy has served as Private Brickell’s Chief Business Officer since 2019. Prior to joining Private Brickell, Mr. Levy served from 2016 through 2019 as Chief Business Officer at miRagen Therapeutics, Inc. Nasdaq: MGEN,a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Between 2000 through 2016 Mr. Levy held multiple investment banking positions at Merrill Lynch, Pierce, Fenner & Smith Incorporated, Jefferies Group and Wedbush Securities Inc. Mr. Levy received a B.S. in applied economics from Cornell University.- Adam Levy自2019年起担任Private Brickell&；8217；S首席商务官。在加入Private Brickell之前，Levy先生于2016年至2019年担任MiragenTherapeutics，Inc.首席商务官纳斯达克股票代码:MGEN，一家临床阶段的生物制药公司，致力于发现和开发专有的RNA靶向疗法，特别关注microRNA及其在医疗需求高度未满足的疾病中的作用。Levy从2000年到2016年在Merrill Lynch，Pierce，Fenner&Smith Incorporated，Jefferies Group和Wedbush Securities Inc.担任多个投资银行职位。Levy先生在康奈尔大学（Cornell University）获得应用经济学学士学位。
- Adam Levy has served as Private Brickell’s Chief Business Officer since 2019. Prior to joining Private Brickell, Mr. Levy served from 2016 through 2019 as Chief Business Officer at miRagen Therapeutics, Inc. Nasdaq: MGEN,a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Between 2000 through 2016 Mr. Levy held multiple investment banking positions at Merrill Lynch, Pierce, Fenner & Smith Incorporated, Jefferies Group and Wedbush Securities Inc. Mr. Levy received a B.S. in applied economics from Cornell University.
- Jon Congleton
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在梯瓦制药工业有限公司（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任梯瓦全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入梯瓦公司之前，康格尔顿曾在赛诺菲的前身公司担任过十年的各种商业职务。康格尔顿先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.- Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在梯瓦制药工业有限公司（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任梯瓦全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入梯瓦公司之前，康格尔顿曾在赛诺菲的前身公司担任过十年的各种商业职务。康格尔顿先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton,has served as Mineralys Therapeutics, Inc. Chief Executive Officer and as a member of Mineralys Therapeutics, Inc. Board since November 2020. Prior to joining Mineralys Therapeutics, Inc. , Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- Brian Taylor Slingsby
Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University.- Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
- Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University.